

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Xyrem (sodium oxybate).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: <u>1-866-331-2104</u>]. If you have any questions or concerns, please call <u>1-866-331-2103</u>. **Requests will not be considered unless this form is complete. The KP-MAS** Formulary can be found at: <u>http://www.providers.kaiserpermanente.org/mas/formulary.html</u>

	1 – Patient Information	
Patient Name:	Kaiser Medical ID#:	Date of Birth:
	2 – Prescriber Information	
Is the prescriber a pulmonologist (sleep	o specialist) or neurologist?	
If consulted with a specialist, specialist	name and specialty:	
Prescriber Name:	Specialty:	NPI:
Prescriber Address:		
Prescriber Phone #:	Prescriber Fax #:	
Please check the boxes that apply: Initial Request	erapy Request	
	3 – Pharmacy Information	
Pharmacy Name:	Pharmacy NPI:	
Pharmacy Phone #	Pharmacy Fax #:	
Sig:		
Drug 2: Name/Strength/Formulation:		

1. Is this request for initial or continuing therapy?

Initial therapy
Continuing therapy, State date: ______

Member has enrolled in Xyrem Patient Success Program? AND
 □ No □ Yes

Treatment of excessive daytime sleepiness in narcolepsy:

- Member has diagnosis of excessive daytime sleepiness in narcolepsy AND
 □ No □ Yes
- Member has had an adequate trial (≥2 months) of a preferred stimulant (methylphenidate, amphetamine salt combination, dextroamphetamine) AND modafinil/armodafinil, unless contraindicated AND
 □ No □ Yes
- Member has had Adequate trial of Sunosi (≥2 months) AND Wakix (≥2 months), unless contraindicated AND
 □ No □ Yes
- 5. Member is 7 years to 65 years of age AND □ No □ Yes
- 6. Member is not on any sedative-hypnotic agents, opioids, benzodiazepines, or alcohol AND □ No □ Yes
- 7. Member has had adequate trial (≥2 months) of Xywav?
 □ No □ Yes

Treatment of cataplexy due to narcolepsy:

- 8. Member has diagnosis of cataplexy due to narcolepsy AND
 □ No □ Yes
- 9. Member has had an adequate trial (≥2 months) of at least 2 of the following: TCAs, SSRI, or SNRI or there is a contraindication AND
 □ No □ Yes
- 10. Patient has had adequate trial (≥2 months) of Xywav? □ No □ Yes

For continuation of therapy, please respond to additional questions below:

- Does the member have documentation of positive clinical response to therapy? AND
 □ No □ Yes
- Has the member continued to be under the care of a specialist? AND
 □ No □ Yes

7 – Prescriber Sign-Off

Additional Information –

- 1. Please submit chart notes/medical records for the patient that are applicable to this request.
- 2. If member has not tried preferred agent(s) please provide rationale/explanation and any additional supporting information that should be taken into consideration for the requested medication:

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Prescriber Signature:	Date:		
Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is			
private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of			
any action in reliance on the contents of this teleconied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility			